Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
2022
March
Monthly Archives: March 2022
Xenpozyme (olipudase alfa) approved in Japan as first and only approved...
31st March 2022
$4 million research program seeks therapy for rare genetic condition ADNP...
30th March 2022
Eagle Pharmaceuticals to acquire Acacia Pharma Group
30th March 2022
Sanofi and IGM Biosciences sign collaboration agreement for IgM antibody agonists
30th March 2022
New analysis shows that Kesimpta®▼ (ofatumumab)-treated adults with relapsing remitting multiple...
28th March 2022
Pfizer granted FDA Breakthrough Therapy Designation for respiratory syncytial virus vaccine...
25th March 2022
Global trials show drug eases symptoms of chronic cough
25th March 2022
Construction begins on facility to support the manufacture of cannabis-based medicines...
25th March 2022
Beckman Coulter achieves CE Mark for its MDW-SARS CoV-2 application as...
23rd March 2022
NHS fast tracks new “gamechanging” drug for lung cancer
22nd March 2022
1
2
3
4
Page 1 of 4
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...